Rohit Rohan Kumar Makol

Founder @Bioleap

Cambridge, GB

Bioleap are a Pharmatech company, leveraging a systems-modelling approach to develop the next generation of biologics by shifting from a drug discovery mindset to a drug engineering one. Their platform combines physics-first biophysical models with AI to enable a ground-breaking shift in our ability to model and simulate complex disease systems and therapeutic intervention, unlocking insights about optimal modalities of therapies with the greatest efficacy. They are targeting the 85% attrition rate at clinical trial for immuno-oncology therapies, which costs pharma $50billion+ year in failed trials, which has been attributed to the lack of quality pre-clinical models. Their underlying patent-pending technology reduces parameter uncertainty by up to 100x compared with existing biophysical or AI approaches, reducing data requirements by 10-20x. This is an order of magnitude shift, unlocking new possibilities for in-silico modelling of large-scale complex disease systems for the first time.

The Wharton School

Quantitative Modelling

University of Leicester

Master of Science - MS, Finance

University of Liverpool

Bachelor of Arts - BA, Law and Business